Publish in this journal
Journal Information
Vol. 71. Issue 2.
Pages 124-125 (February 2018)
Vol. 71. Issue 2.
Pages 124-125 (February 2018)
Scientific letter
Full text access
Selection of the Best of 2017 in Ischemic Heart Disease
Selección de lo mejor del año 2017 en cardiopatía isquémica
Roberto Martín-Asenjoa,
Corresponding author

Corresponding author:
, Jaime Aboalb, Josep Masipc, Esteban López de Sád, Alessandro Sionise
a Servicio de Cardiología, Hospital 12 de Octubre, Madrid, Spain
b Servicio de Cardiología, Hospital Universitario Doctor Josep Trueta, Girona, Spain
c Servicio de Cardiología, Hospital Sanitas CIMA, Barcelona; Servei de Medicina Intensiva, Consorci Sanitari Integral, Universitat de Barcelona, Barcelona, Spain
d Unidad Coronaria, Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
e Unidad de Cuidados Agudos Cardiológicos, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, CIBER-CV, Universidad Autónoma de Barcelona, Barcelona, Spain
Related content
Rev Esp Cardiol. 2018;71:123-410.1016/j.rec.2017.10.034
Jaime Aboal, Esteban López de Sá, Roberto Martín-Asenjo, Josep Masip, Alessandro Sionis
Article information
Full Text
Download PDF
Full Text
To the Editor,

Here, we summarize 6 salient articles published in 2017 covering various aspects related to ischemic heart disease.

In the area of secondary cardiovascular prevention, there are 3 articles in particular that could prompt significant changes in strategies aimed at reducing long-time risk in patients with ischemic heart disease. First, the FOURIER trial1 compared the efficacy and safety of evolocumab (a PCSK9 inhibitor) with that of placebo in 27 564 statin-treated patients with atherosclerotic cardiovascular disease and low-density lipoprotein-cholesterol (LDL-C) ≥ 70mg/dL. During follow-up (median, 2.2 years), the group treated with evolocumab experienced a marked drop in LDL-C (median reduction, 30mg/dL) and a significant decrease in cardiovascular events (9.8% in the evolocumab group vs 11.3% in the placebo group), without differences in severe adverse effects.

The second article analyzed the antithrombotic regimens of patients with chronic ischemic heart disease. The researchers in the COMPASS trial2 randomized 27 395 patients to rivaroxaban (2.5mg/12h) plus aspirin (100mg/d), rivaroxaban (5mg/12h), or aspirin (100mg/d). The study was prematurely stopped (mean follow-up, 23 months) due to the superiority of rivaroxaban plus aspirin in the reduction of the primary outcome (composite of cardiovascular death, stroke, and myocardial infarction) vs aspirin alone (4.1% vs 5.4%; P < .001). Although the combination strategy was accompanied by higher incidence of major bleeding (3.1% vs 1.9%; P < .001), there were no significant differences in intracranial or fatal bleeding.

In addition to novelties in the control of risk factors and optimization of antithrombotic therapy, the CANTOS clinical trial3 has put the focus back on inflammation as a key element in the genesis of residual risk in stable ischemic heart disease. The study evaluated the efficacy and safety of canakinumab (monoclonal antibody inhibitor of interleukin-1) vs placebo in 10 061 patients with previous myocardial infarction and persistent inflammatory activity (elevated C-reactive protein). After a 48-month follow-up, patients treated with subcutaneous canakinumab 150mg every 3 months had lower incidence of the composite primary end point (cardiovascular death, stroke, and cardiovascular events) than those treated with placebo (3.86 vs 4.50 events per 100 person-years; hazard ratio [HR] = 0.85; 95% confidence interval [95%CI], 0.74-0.98; P = .021).

Regarding acute coronary syndromes (ACSs), a noteworthy study examined myocardial infarction screening in patients attending for chest pain. Boeddinghaus et al.4 compared the 4 validated strategies involving high-sensitivity troponin I (hs-cTnI): limit of detection (hs-cTnI < 2 ng/L), single cutoff point (hs-cTnI < 5 ng/L), 1-hour algorithm (hs-cTnI < 5 ng/L and 1-h change < 2 ng/L), and the 0/1-hour algorithm recommended by the European Society of Cardiology (combination of the limit of detection and the 1-hour algorithm). The authors prospectively included 2828 unselected patients who presented with suspected myocardial infarction. The 4 algorithms showed an adequate diagnostic validity, although the single cutoff point was less sensitive than the other 3 algorithms in early presenters (within 2hours of symptom onset).

The PROSPERO meta-analysis of non-ST-segment elevation ACS, by Jobs et al.,5 included 8 clinical trials with 5324 patients randomized to either early or delayed invasive treatment. In the overall analysis, the early invasive strategy failed to improve survival. Nonetheless, this strategy significantly reduced mortality in some prespecified subgroups: those with elevated biomarkers at admission (HR = 0.761; 95%CI, 0.581-0.996), diabetes (HR = 0.67; 95%CI, 0.45-0.99), GRACE score > 140 (HR = 0.70; 95%CI, 0.52-0.95), and age ≥ 75 years (HR = 0.65; 95%CI, 0.46-0.93), even if the interactions among these factors failed to show conclusive results in statistical testing.

Regarding ST-segment elevation ACS, in addition to the recent publication of the new European guidelines, whose breadth surpasses the aims of this letter, the COMPARE-ACUTE clinical trial6 was performed to clarify the benefit of PCI of noninfarct-related coronary arteries in patients with multivessel disease. Accordingly, 885 patients with ST-segment elevation ACS and multivessel disease treated with primary PCI of the infarct-related artery were randomized to either fractional flow reserve-guided complete revascularization or no revascularization of noninfarct-related arteries. The patients assigned to the fractional flow reserve-guided complete revascularization had lower incidence of the primary composite end point of cardiovascular death, myocardial infarction, stroke, or repeat revascularization (8% vs 21%; HR = 0.35; 95%CI, 0.22-0.55; P < .001), largely due to the variable new revascularization, defined as urgent revascularizations at any time or elective revascularizations performed within 45 days.

M.S. Sabatine, R.P. Giugliano, A.C. Keech, et al.
Evolocumab and clinical outcomes in patients with cardiovascular disease.
N Engl J Med., 376 (2017), pp. 1713-1722
J.W. Eikelboom, S.J. Connolly, J. Bosch, et al.
Rivaroxaban with or without aspirin in stable cardiovascular disease.
Consultado 31 Ago 2017
P.M. Ridker, B.M. Everett, T. Thuren, et al.
Antiinflammatory therapy with canakinumab for atherosclerotic disease.
Consultado 31 Ago 2017
J. Boeddinghaus, T. Nestelberger, R. Twerenbold, et al.
Direct comparison of 4 very early rule-out strategies for acute myocardial infarction using high-sensitivity cardiac troponin I.
Circulation., 135 (2017), pp. 1597-1611
A. Jobs, S.R. Mehta, G. Montalescot, et al.
Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.
Lancet., 390 (2017), pp. 737-746
P.C. Smits, M. Abdel-Wahab, F.J. Neumann, et al.
Fractional flow reserve-guided multivessel angioplasty in myocardial infarction.
N Engl J Med., 376 (2017), pp. 1234-1244
Copyright © 2017. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?